HomeCompareAVVH vs JNJ

AVVH vs JNJ: Dividend Comparison 2026

AVVH yields 66666.67% · JNJ yields 2.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 AVVH wins by $8.441837856534449e+24M in total portfolio value
10 years
AVVH
AVVH
● Live price
66666.67%
Share price
$0.00
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$8.441837856534449e+24M
Annual income
$8,417,001,582,403,749,000,000,000,000,000.00
Full AVVH calculator →
JNJ
Johnson & Johnson
● Live price
2.13%
Share price
$244.44
Annual div
$5.20
5Y div CAGR
28%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$30.3K
Annual income
$4,689.40
Full JNJ calculator →

Portfolio growth — AVVH vs JNJ

📍 AVVH pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodAVVHJNJ
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, AVVH + JNJ cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
AVVH pays
JNJ pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

AVVH
Annual income on $10K today (after 15% tax)
$5,666,666.67/yr
After 10yr DRIP, annual income (after tax)
$7,154,451,345,043,187,000,000,000,000,000.00/yr
JNJ
Annual income on $10K today (after 15% tax)
$180.82/yr
After 10yr DRIP, annual income (after tax)
$3,985.99/yr
At 15% tax rate, AVVH beats the other by $7,154,451,345,043,187,000,000,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of AVVH + JNJ for your $10,000?

AVVH: 50%JNJ: 50%
100% JNJ50/50100% AVVH
Portfolio after 10yr
$4.2209189282672247e+24M
Annual income
$4,208,500,791,201,874,400,000,000,000,000.00/yr
Blended yield
99.71%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on JNJ right now

AVVH
No analyst data
Altman Z
-27.1
Piotroski
3/9
JNJ
Analyst Ratings
20
Buy
17
Hold
3
Sell
Consensus: Buy
Price Target
$228.73
-6.4% upside vs current
Range: $190.00 — $265.00
Altman Z
5.2
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

AVVH buys
0
JNJ buys
8
PoliticianChamberTickerTypeAmountDate
Thomas H. Kean🏢 House$JNJ▼ Sell$15,001 - $50,0002026-01-23
Julie Johnson🏢 House$JNJ▼ Sell$1,001 - $15,0002025-12-18
Lloyd Doggett🏢 House$JNJ▲ Buy$1,001 - $15,0002025-12-09
Thomas H. Kean🏢 House$JNJ▼ Sell$15,001 - $50,0002025-11-20
Julie Johnson🏢 House$JNJ▼ Sell$1,001 - $15,0002025-11-13
Rich McCormick🏢 House$JNJ▲ Buy$1,001 - $15,0002025-11-05
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Jared Moskowitz🏢 House$JNJ▼ Sell$1,001 - $15,0002025-10-10
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricAVVHJNJ
Forward yield66666.67%2.13%
Annual dividend / share$2.00$5.20
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%28%
Portfolio after 10y$8.441837856534449e+24M$30.3K
Annual income after 10y$8,417,001,582,403,749,000,000,000,000,000.00$4,689.40
Total dividends collected$8.44020886744369e+24M$15.4K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: AVVH vs JNJ ($10,000, DRIP)

YearAVVH PortfolioAVVH Income/yrJNJ PortfolioJNJ Income/yrGap
1← crossover$6,677,367$6,666,666.67$10,592$272.30+$6.67MAVVH
2$4,167,497,846$4,160,353,063.34$11,289$357.73+$4167.49MAVVH
3$2,431,161,901,635$2,426,702,678,939.67$12,123$472.89+$2431161.89MAVVH
4$1,325,636,209,022,888$1,323,034,865,788,139.00$13,141$629.86+$1325636209.01MAVVH
5$675,632,775,263,916,700$674,214,344,520,262,300.00$14,408$846.81+$675632775263.90MAVVH
6$321,867,481,182,444,260,000$321,144,554,112,911,900,000.00$16,021$1,151.60+$321867481182444.25MAVVH
7$143,326,993,661,751,470,000,000$142,982,595,456,886,240,000,000.00$18,122$1,588.22+$143326993661751472.00MAVVH
8$59,657,925,421,851,500,000,000,000$59,504,565,538,633,426,000,000,000.00$20,930$2,228.20+$59657925421851500544.00MAVVH
9$23,211,471,150,187,795,000,000,000,000$23,147,637,169,986,416,000,000,000,000.00$24,792$3,191.91+$2.3211471150187796e+22MAVVH
10$8,441,837,856,534,450,000,000,000,000,000$8,417,001,582,403,749,000,000,000,000,000.00$30,274$4,689.40+$8.441837856534449e+24MAVVH

AVVH vs JNJ: Complete Analysis 2026

AVVHStock

AVVAA World Health Care Products, Inc. provides natural and therapeutic skin care products worldwide. The company is a biotechnology company which primarily focuses on manufacturing and marketing over-the-counter the Neuroskin line of products used for the treatment of skin abnormalities, and to enhance the natural clarity and texture of healthy skin through mass marketing food and drug channels. It also has distribution rights for patented European skin care products, which are scientifically developed to treat the symptoms of skin diseases, including eczema, psoriasis, and acne. The company also offers a line of natural animal care products, which is a grooming treatment for dogs, cats, horses, and other pets. AVVAA World Health Care Products, Inc. was incorporated in 1998 and is based in Richmond, Virginia. As of June 23, 2021, AVVAA World Health Care Products, Inc. operates as a subsidiary of Gold Quest Capital, Inc.

Full AVVH Calculator →

JNJHealthcare

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.

Full JNJ Calculator →
📬

Get this AVVH vs JNJ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

AVVH vs SCHDAVVH vs JEPIAVVH vs OAVVH vs KOAVVH vs MAINAVVH vs ABBVAVVH vs MRKAVVH vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.